董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jerome D. Jabbour | 男 | Chairman, Chief Executive Officer, President and Interim Chief Financial Officer | 51 | 65.50万美元 | 19.08 | 2026-03-31 |
| Evelyn D'An | 女 | Director | 64 | 6.29万美元 | 未持股 | 2026-03-31 |
| Edward Neugeboren | 男 | Director | 58 | 5.46万美元 | 未持股 | 2026-03-31 |
| Robin L. Smith | 女 | Director | 65 | 5.42万美元 | 未持股 | 2026-03-31 |
| Keith Murphy | 男 | Director | 55 | 5.17万美元 | 未持股 | 2026-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jerome D. Jabbour | 男 | Chairman, Chief Executive Officer, President and Interim Chief Financial Officer | 51 | 65.50万美元 | 19.08 | 2026-03-31 |
董事简历
中英对照 | 中文 | 英文- Jerome D. Jabbour
-
JeromeD.Jabbour于2018年3月被任命为首席执行官。他自2016年3月起担任我们的总裁。此前，他曾担任我们的执行Vice President、首席商务官、总法律顾问和秘书（2013年10月以来），以及我们的董事之一（2012年4月至2013年11月）。Jabbour先生也是Matinas Biopharma的联合创始人。在加入我们的管理团队之前，他于2012年至2013年10月担任MediMedia USA或MediMedia的执行Vice President and General Counsel，这是一家私人控股的多元化医疗保健服务公司。此前，他曾担任Wockhardt Limited公司（全球制药和生物技术公司）（2008年至2012年）的高级副总裁，的全球法律事务主管，以及Reliant公司的高级法律顾问兼助理秘书（2004年至2008年）。职业生涯早期，他曾担任Alpharma，Inc.的商业顾问（2003年至2004年），以及Lowenstein Sandler LLP的公司助理（1999年至2003年）。Jabbour先生在新泽西的Seton Hall University School of Law获得法学博士学位，在巴尔的摩的Loyola University获得心理学学士学位。
Jerome D. Jabbour was appointed Chief Executive Officer in March 2018 and was named Chairman in March 2025. He has served as Matinas Biopharma Holdings, Inc.'s President since March 2016. Prior to that he served as Matinas Biopharma Holdings, Inc.'s Executive Vice President, Chief Business Officer, General Counsel and Secretary since October 2013 and as one of Matinas Biopharma Holdings, Inc.'s directors from April 2012 until November 2013. Mr. Jabbour is also a Co founder of Matinas BioPharma. Jabbour has also served on the board of directors of Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments since February 2026. Prior to joining Matinas Biopharma Holdings, Inc.'s management team, he was the Executive Vice President and General Counsel of MediMedia USA, or MediMedia, from 2012 to October 2013, a privately held diversified healthcare services company. Prior to MediMedia, he was the Senior Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008 2012), a global pharmaceutical and biotechnology company, and Senior Counsel and Assistant Secretary at Reliant (2004 2008). Earlier in his career, he held positions as Commercial Counsel at Alpharma, Inc. (2003 2004) and as a Corporate Associate at Lowenstein Sandler LLP (1999 2003). Mr. Jabbour earned his J.D. from Seton Hall University School of Law in New Jersey and a B.A. in Psychology from Loyola University in Baltimore. - JeromeD.Jabbour于2018年3月被任命为首席执行官。他自2016年3月起担任我们的总裁。此前，他曾担任我们的执行Vice President、首席商务官、总法律顾问和秘书（2013年10月以来），以及我们的董事之一（2012年4月至2013年11月）。Jabbour先生也是Matinas Biopharma的联合创始人。在加入我们的管理团队之前，他于2012年至2013年10月担任MediMedia USA或MediMedia的执行Vice President and General Counsel，这是一家私人控股的多元化医疗保健服务公司。此前，他曾担任Wockhardt Limited公司（全球制药和生物技术公司）（2008年至2012年）的高级副总裁，的全球法律事务主管，以及Reliant公司的高级法律顾问兼助理秘书（2004年至2008年）。职业生涯早期，他曾担任Alpharma，Inc.的商业顾问（2003年至2004年），以及Lowenstein Sandler LLP的公司助理（1999年至2003年）。Jabbour先生在新泽西的Seton Hall University School of Law获得法学博士学位，在巴尔的摩的Loyola University获得心理学学士学位。
- Jerome D. Jabbour was appointed Chief Executive Officer in March 2018 and was named Chairman in March 2025. He has served as Matinas Biopharma Holdings, Inc.'s President since March 2016. Prior to that he served as Matinas Biopharma Holdings, Inc.'s Executive Vice President, Chief Business Officer, General Counsel and Secretary since October 2013 and as one of Matinas Biopharma Holdings, Inc.'s directors from April 2012 until November 2013. Mr. Jabbour is also a Co founder of Matinas BioPharma. Jabbour has also served on the board of directors of Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments since February 2026. Prior to joining Matinas Biopharma Holdings, Inc.'s management team, he was the Executive Vice President and General Counsel of MediMedia USA, or MediMedia, from 2012 to October 2013, a privately held diversified healthcare services company. Prior to MediMedia, he was the Senior Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008 2012), a global pharmaceutical and biotechnology company, and Senior Counsel and Assistant Secretary at Reliant (2004 2008). Earlier in his career, he held positions as Commercial Counsel at Alpharma, Inc. (2003 2004) and as a Corporate Associate at Lowenstein Sandler LLP (1999 2003). Mr. Jabbour earned his J.D. from Seton Hall University School of Law in New Jersey and a B.A. in Psychology from Loyola University in Baltimore.
- Evelyn D'An
-
Evelyn D'An自2025年2月起在董事会任职。她是一位经验丰富的董事会成员和财务领袖，在公司治理、财务监督和会计方面对多类公司拥有丰富经验。她是D'An Financial Services的总裁——这是一家由她于2004年创立的战略咨询公司，自2006年起她开始在各公司董事会任职。1998年至2004年间，D'An女士曾任会计与专业服务公司安永（Ernst & Young）的合伙人，在此之前她在安永累计服务18年，为零售、消费品、科技、金融服务、媒体等多个行业的客户提供服务。D'An女士现任以下公司董事：Zoomcar Holdings, Inc.（纳斯达克代码：ZCAR），一家上市的共享汽车平台公司，自2023年4月起任职；GHD Group Pty Ltd.，一家私营的技术型专业服务公司，自2020年3月起任职；Backblaze, Inc.（纳斯达克代码：BLZE），一家上市的开放云存储平台公司，自2021年8月起任职。她在上述三家公司均担任审计委员会主席，同时是Backblaze, Inc.和Zoomcar Holdings, Inc.的薪酬委员会成员，以及GHD Group Pty Ltd.的提名委员会成员。D'An女士曾于2018年4月至2021年6月在Renovaro Inc.（纳斯达克代码：REND，前称Enochian BioSciences Inc.）的董事会任职，期间为审计委员会和提名委员会成员。D'An女士毕业于纽约州立大学奥尔巴尼分校，获得会计学理学士学位。
Evelyn D'An has served on the Board since February 2025. She is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of companies She is President of D'An Financial Services, a strategic consulting firm she established in 2004 and has been serving on corporate boards since 2006. From 1998 through 2004, Ms. D'An served as partner of Ernst & Young, an accounting and professional services firm, where she spent 18 years serving clients in retail, consumer products, technology, financial services, media and other sectors. Ms. D'An serves on the board of directors of Zoomcar Holdings, Inc., a publicly traded car sharing platform company (NASDAQ: ZCAR), where she has served since April 2023, GHD Group Pty Ltd., a privately held technical professional services firm, where she has served since March 2020, and Backblaze, Inc., a publicly traded open cloud storage platform (NASDAQ: BLZE), where she has served since August 2021. Ms. D'An is the chair of the audit committee of all three companies, a member of the compensation committee of Backblaze, Inc. and Zoomcar Holdings, Inc. and a member of the nominating committee of GHD Group Pty Ltd. Ms. D'An served on the board of directors of Renovaro Inc. (NASDAQ: REND) (formerly Enochian BioSciences Inc.) from April 2018 through June 2021, where she was a member of the audit committee and the nominating committee. Ms. D'An graduated with a B.S. in Accounting from the State University at Albany. - Evelyn D'An自2025年2月起在董事会任职。她是一位经验丰富的董事会成员和财务领袖，在公司治理、财务监督和会计方面对多类公司拥有丰富经验。她是D'An Financial Services的总裁——这是一家由她于2004年创立的战略咨询公司，自2006年起她开始在各公司董事会任职。1998年至2004年间，D'An女士曾任会计与专业服务公司安永（Ernst & Young）的合伙人，在此之前她在安永累计服务18年，为零售、消费品、科技、金融服务、媒体等多个行业的客户提供服务。D'An女士现任以下公司董事：Zoomcar Holdings, Inc.（纳斯达克代码：ZCAR），一家上市的共享汽车平台公司，自2023年4月起任职；GHD Group Pty Ltd.，一家私营的技术型专业服务公司，自2020年3月起任职；Backblaze, Inc.（纳斯达克代码：BLZE），一家上市的开放云存储平台公司，自2021年8月起任职。她在上述三家公司均担任审计委员会主席，同时是Backblaze, Inc.和Zoomcar Holdings, Inc.的薪酬委员会成员，以及GHD Group Pty Ltd.的提名委员会成员。D'An女士曾于2018年4月至2021年6月在Renovaro Inc.（纳斯达克代码：REND，前称Enochian BioSciences Inc.）的董事会任职，期间为审计委员会和提名委员会成员。D'An女士毕业于纽约州立大学奥尔巴尼分校，获得会计学理学士学位。
- Evelyn D'An has served on the Board since February 2025. She is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of companies She is President of D'An Financial Services, a strategic consulting firm she established in 2004 and has been serving on corporate boards since 2006. From 1998 through 2004, Ms. D'An served as partner of Ernst & Young, an accounting and professional services firm, where she spent 18 years serving clients in retail, consumer products, technology, financial services, media and other sectors. Ms. D'An serves on the board of directors of Zoomcar Holdings, Inc., a publicly traded car sharing platform company (NASDAQ: ZCAR), where she has served since April 2023, GHD Group Pty Ltd., a privately held technical professional services firm, where she has served since March 2020, and Backblaze, Inc., a publicly traded open cloud storage platform (NASDAQ: BLZE), where she has served since August 2021. Ms. D'An is the chair of the audit committee of all three companies, a member of the compensation committee of Backblaze, Inc. and Zoomcar Holdings, Inc. and a member of the nominating committee of GHD Group Pty Ltd. Ms. D'An served on the board of directors of Renovaro Inc. (NASDAQ: REND) (formerly Enochian BioSciences Inc.) from April 2018 through June 2021, where she was a member of the audit committee and the nominating committee. Ms. D'An graduated with a B.S. in Accounting from the State University at Albany.
- Edward Neugeboren
-
Edward Neugeboren在制药业务、商业发展、企业管理、投资银行、资产管理和机构股权研究方面拥有超过30年的医疗保健经验。自2016年1月起，Neugeboren先生担任Cronus Pharma，LLC的首席战略官，该公司是一家完全整合的研发、制造、销售和营销制药公司，Kavuru先生是该公司的负责人。Neugebroren先生领导Cronus Pharma的商业运营、战略规划和收购，还负责制定和执行整体公司战略以及公司和投资组合的收购和许可。此前，Neugeboren先生是母公司制药集团的首席战略官，该集团由仿制药公司Rising Pharma Holdings，Inc.和专业制药公司Casper Pharma，LLC组成。此外，Neugeboren先生是QuadView Healthcare Advisors的创始人和管理合伙人，该公司以前名为ArcLight Advisors，LLC，一家医疗保健投资银行和商业发展公司。Neugeboren先生以前是Ledgemont Capital Group有限责任公司的董事总经理，该公司是一家为新兴的医疗保健和技术公司提供战略和财务咨询服务的投资银行公司。Neugeboren先生还是Third Ridge Capital Management，LLC的管理合伙人，Third Ridge Capital Management，LLC是一家做多/做空美国股票的对冲基金。Neugeboren先生是Ledgemont Capital Group有限责任公司的管理成员，该公司于2013年5月申请自愿破产。Neugeboren先生拥有Finra系列24、7和63安全执照，并从联合学院获得经济学学士学位。
Edward Neugeboren has over three decades of healthcare experience in pharmaceutical operations, business development, corporate management, investment banking, asset management, and institutional equity research. Since June 2013, Mr. Neugeboren has served as the Founder and Managing Partner of QuadView Healthcare Advisors, a healthcare investment banking and business development advisory firm. From January 2016 to October 2025, Mr. Neugeboren served as the Chief Strategy Officer of Cronus Pharma, LLC, a fully integrated R&D, manufacturing, and sales & marketing pharmaceutical company and at which Mr. Neugeboren is a principal. Mr. Neugeboren led Cronus Pharma's commercial operations, strategic planning and acquisitions and was also responsible for developing and executing overall corporate strategy as well as corporate and portfolio acquisitions and licensing. Since March 2025, Mr. Neugeboren has served on the Board of Directors of Matinas Biopharma, Inc. Previously, Mr. Neugeboren was the Chief Strategy Officer for the parent pharmaceutical group comprised of Rising Pharma Holdings, Inc., a generic pharmaceutical company, and Casper Pharma, LLC, a specialty pharmaceutical company. Mr. Neugeboren was previously a Managing Director of Ledgemont Capital Group, LLC, an investment banking firm providing strategic and financial advisory services to emerging healthcare and technology companies. Mr. Neugeboren was also a Managing Partner of Third Ridge Capital Management, LLC, a long/short U.S. equity hedge fund. Mr. Neugeboren holds Series 24, 7 and 63 FINRA security licenses and graduated with a BA in Economics from Union College. - Edward Neugeboren在制药业务、商业发展、企业管理、投资银行、资产管理和机构股权研究方面拥有超过30年的医疗保健经验。自2016年1月起，Neugeboren先生担任Cronus Pharma，LLC的首席战略官，该公司是一家完全整合的研发、制造、销售和营销制药公司，Kavuru先生是该公司的负责人。Neugebroren先生领导Cronus Pharma的商业运营、战略规划和收购，还负责制定和执行整体公司战略以及公司和投资组合的收购和许可。此前，Neugeboren先生是母公司制药集团的首席战略官，该集团由仿制药公司Rising Pharma Holdings，Inc.和专业制药公司Casper Pharma，LLC组成。此外，Neugeboren先生是QuadView Healthcare Advisors的创始人和管理合伙人，该公司以前名为ArcLight Advisors，LLC，一家医疗保健投资银行和商业发展公司。Neugeboren先生以前是Ledgemont Capital Group有限责任公司的董事总经理，该公司是一家为新兴的医疗保健和技术公司提供战略和财务咨询服务的投资银行公司。Neugeboren先生还是Third Ridge Capital Management，LLC的管理合伙人，Third Ridge Capital Management，LLC是一家做多/做空美国股票的对冲基金。Neugeboren先生是Ledgemont Capital Group有限责任公司的管理成员，该公司于2013年5月申请自愿破产。Neugeboren先生拥有Finra系列24、7和63安全执照，并从联合学院获得经济学学士学位。
- Edward Neugeboren has over three decades of healthcare experience in pharmaceutical operations, business development, corporate management, investment banking, asset management, and institutional equity research. Since June 2013, Mr. Neugeboren has served as the Founder and Managing Partner of QuadView Healthcare Advisors, a healthcare investment banking and business development advisory firm. From January 2016 to October 2025, Mr. Neugeboren served as the Chief Strategy Officer of Cronus Pharma, LLC, a fully integrated R&D, manufacturing, and sales & marketing pharmaceutical company and at which Mr. Neugeboren is a principal. Mr. Neugeboren led Cronus Pharma's commercial operations, strategic planning and acquisitions and was also responsible for developing and executing overall corporate strategy as well as corporate and portfolio acquisitions and licensing. Since March 2025, Mr. Neugeboren has served on the Board of Directors of Matinas Biopharma, Inc. Previously, Mr. Neugeboren was the Chief Strategy Officer for the parent pharmaceutical group comprised of Rising Pharma Holdings, Inc., a generic pharmaceutical company, and Casper Pharma, LLC, a specialty pharmaceutical company. Mr. Neugeboren was previously a Managing Director of Ledgemont Capital Group, LLC, an investment banking firm providing strategic and financial advisory services to emerging healthcare and technology companies. Mr. Neugeboren was also a Managing Partner of Third Ridge Capital Management, LLC, a long/short U.S. equity hedge fund. Mr. Neugeboren holds Series 24, 7 and 63 FINRA security licenses and graduated with a BA in Economics from Union College.
- Robin L. Smith
-
Robin L. Smith，自2015年起担任私人持股的战略和投资咨询公司BRM Holdings的管理合伙人。从2006年到2015年，史密斯博士担任上市干细胞库Lisata Therapeutics，Inc.（纳斯达克股票代码：LSTA）（前身为Neostem，Inc.）的董事长兼首席执行官。从2019年10月到2023年12月，史密斯博士在Celularity公司的董事会任职，该公司是一家上市的细胞和再生医学公司（纳斯达克股票代码：CELU）。2020年2月至2022年5月，史密斯博士在ServiceSource International，Inc.的董事会任职，该公司是一家上市的客户旅程体验公司（纳斯达克股票代码：SREV），于2022年被Concentrix Corporation收购，并在其提名和治理委员会任职。从2019年12月到2021年11月，史密斯博士在索伦托医疗的董事会任职，该公司曾是一家上市的临床和商业阶段生物制药公司（纳斯达克股票代码：SRNE）。从2019年2月到2020年5月，Smith博士曾在Seelos Therapeutics的董事会任职，该公司是一家上市的临床阶段生物制药公司（纳斯达克股票代码：SEEL），并在其审计和薪酬委员会任职。在2019年之前，史密斯博士曾在多家上市生物制药公司的董事会任职。史密斯博士获得了耶鲁大学的学士学位和耶鲁大学医学院的医学博士学位。她拥有沃顿商学院的工商管理硕士学位，完成了斯坦福大学董事课程，并获得了托马斯杰斐逊医学院的荣誉理学博士学位。
Robin L. Smith has served on the Board since February 2025. Dr. Smith has been a Managing Partner of BRM Holdings, a privately held strategic and investment advisory firm, since 2015. She also founded two privately held biotechnology companies, Spiritus Therapeutics and Exotropin LLC. Dr Smith also served as an independent director of the Western Acquisition Ventures Corp., a special purpose acquisition company, from 2022 2023, where she served on the audit and compensation committees. From 2006 until 2015, Dr. Smith was chairman and chief executive officer of Lisata Therapeutics, Inc., a publicly traded stem cell bank (NASDAQ: LSTA) (formerly Neostem, Inc.). From October 2019 to December 2023, Dr. Smith served on the board of directors of Celularity Inc, a publicly traded cellular and regenerative medicine company (NASDAQ: CELU). From February 2020 to May 2022, Dr. Smith served on the board of directors of ServiceSource International, Inc., a publicly traded customer journey experience company (NASDAQ: SREV) that was acquired in 2022 by Concentrix Corporation, and served on its nominating and governance committee. From December 2019 to November 2021, Dr. Smith served on the board of directors of Sorrento Therapeutics, a former publicly traded clinical and commercial stage biopharmaceutical company (NASDAQ: SRNE). From February 2019 to May 2020, Dr. Smith served on the board of directors of Seelos Therapeutics, a publicly traded clinical stage biopharmaceutical company (NASDAQ: SEEL), and served on its audit and compensation committees. Prior to 2019, Dr. Smith served on the boards of multiple publicly traded biopharmaceutical companies. Dr. Smith received her B.A. from Yale University and her M.D. from the Yale School of Medicine. She holds an M.B.A. from the Wharton School of Business, completed the Stanford University Directors Program, and received an honorary Doctor of Science degree from Thomas Jefferson Medical College. - Robin L. Smith，自2015年起担任私人持股的战略和投资咨询公司BRM Holdings的管理合伙人。从2006年到2015年，史密斯博士担任上市干细胞库Lisata Therapeutics，Inc.（纳斯达克股票代码：LSTA）（前身为Neostem，Inc.）的董事长兼首席执行官。从2019年10月到2023年12月，史密斯博士在Celularity公司的董事会任职，该公司是一家上市的细胞和再生医学公司（纳斯达克股票代码：CELU）。2020年2月至2022年5月，史密斯博士在ServiceSource International，Inc.的董事会任职，该公司是一家上市的客户旅程体验公司（纳斯达克股票代码：SREV），于2022年被Concentrix Corporation收购，并在其提名和治理委员会任职。从2019年12月到2021年11月，史密斯博士在索伦托医疗的董事会任职，该公司曾是一家上市的临床和商业阶段生物制药公司（纳斯达克股票代码：SRNE）。从2019年2月到2020年5月，Smith博士曾在Seelos Therapeutics的董事会任职，该公司是一家上市的临床阶段生物制药公司（纳斯达克股票代码：SEEL），并在其审计和薪酬委员会任职。在2019年之前，史密斯博士曾在多家上市生物制药公司的董事会任职。史密斯博士获得了耶鲁大学的学士学位和耶鲁大学医学院的医学博士学位。她拥有沃顿商学院的工商管理硕士学位，完成了斯坦福大学董事课程，并获得了托马斯杰斐逊医学院的荣誉理学博士学位。
- Robin L. Smith has served on the Board since February 2025. Dr. Smith has been a Managing Partner of BRM Holdings, a privately held strategic and investment advisory firm, since 2015. She also founded two privately held biotechnology companies, Spiritus Therapeutics and Exotropin LLC. Dr Smith also served as an independent director of the Western Acquisition Ventures Corp., a special purpose acquisition company, from 2022 2023, where she served on the audit and compensation committees. From 2006 until 2015, Dr. Smith was chairman and chief executive officer of Lisata Therapeutics, Inc., a publicly traded stem cell bank (NASDAQ: LSTA) (formerly Neostem, Inc.). From October 2019 to December 2023, Dr. Smith served on the board of directors of Celularity Inc, a publicly traded cellular and regenerative medicine company (NASDAQ: CELU). From February 2020 to May 2022, Dr. Smith served on the board of directors of ServiceSource International, Inc., a publicly traded customer journey experience company (NASDAQ: SREV) that was acquired in 2022 by Concentrix Corporation, and served on its nominating and governance committee. From December 2019 to November 2021, Dr. Smith served on the board of directors of Sorrento Therapeutics, a former publicly traded clinical and commercial stage biopharmaceutical company (NASDAQ: SRNE). From February 2019 to May 2020, Dr. Smith served on the board of directors of Seelos Therapeutics, a publicly traded clinical stage biopharmaceutical company (NASDAQ: SEEL), and served on its audit and compensation committees. Prior to 2019, Dr. Smith served on the boards of multiple publicly traded biopharmaceutical companies. Dr. Smith received her B.A. from Yale University and her M.D. from the Yale School of Medicine. She holds an M.B.A. from the Wharton School of Business, completed the Stanford University Directors Program, and received an honorary Doctor of Science degree from Thomas Jefferson Medical College.
- Keith Murphy
-
Keith Murphy，重新加入Organovo Holdings， Inc.。他曾担任Organovo Holdings， Inc.的董事。自2020年9月起担任执行主席。他是Viscient Biosciences， Inc.（“Viscient”）的首席执行官兼董事长，这是他于2017年创立的一家私营公司，专注于利用3D组织技术和多组学（基因组学、转录组学、代谢组学）的药物发现和开发。2012年2月至2017年4月，他担任Organovo的总裁兼首席执行官；2012年2月至2017年8月，担任董事长。2007年8月至2012年2月，他曾担任Organovo， Inc. （Organovo的主要运营公司，上市交易前）的总裁、首席执行官和董事长。在创立Organovo之前，从1997年8月到2007年7月，Murphy先生在Amgen， Inc.担任各种职务，包括骨质疏松症/骨癌药物Prolia/Xgeva （denosumab）的全球运营主管。加入Amgen之前，从1993年7月到1997年7月，Murphy先生在Alkermes， Inc.（生物技术公司）任职，在那里他担任他们的第一个批准产品Nutropin （hGH） Depot的开发团队的角色。Murphy先生从2020年8月到2022年2月担任Kintara Therapeutics， Inc.的董事会成员，并在其薪酬委员会、提名和公司治理委员会任职。他持有麻省理工学院化学工程学士学位，是加州大学洛杉矶分校安德森管理学院的校友。
Keith Murphy re joined the company's Board in July 2020 and has served as the company's Executive Chairman since September 2020. Mr. Murphy is the Chief Executive Officer and Chairman of Viscient Biosciences, Inc. ("Viscient"), a private company that he founded in 2017 that is focused on drug discovery and development utilizing 3D tissue technology and multi omics (genomics, transcriptomics, metabolomics). Mr. Murphy previously served as the company's President and Chief Executive Officer from February 2012 through April 2017, and as Chairman from February 2012 through August 2017. Mr. Murphy also previously served as President, Chief Executive Officer, and Chairman of Organovo, Inc., the company's primary operating company prior to its going public transaction, from August 2007 to February 2012. Prior to founding Organovo, Inc., Mr. Murphy served in various roles at Amgen, Inc. from August 1997 to July 2007 including as Global Operations Leader for the osteoporosis/bone cancer drug Prolia/Xgeva (denosumab). Prior to joining Amgen, Mr. Murphy served at Alkermes, Inc., a biotechnology company, from July 1993 to July 1997, where he played a role on the development team for their first approved product, Nutropin (hGH) Depot. Mr. Murphy has served as a member of the board of directors of Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) since March 2025 and served as a member of the board of directors of Kintara Therapeutics, Inc. from August 2020 to February 2022, and served on its compensation committee and nominating and corporate governance committee. He holds a B.S. in Chemical Engineering from MIT and is an alumnus of the UCLA Anderson School of Management. - Keith Murphy，重新加入Organovo Holdings， Inc.。他曾担任Organovo Holdings， Inc.的董事。自2020年9月起担任执行主席。他是Viscient Biosciences， Inc.（“Viscient”）的首席执行官兼董事长，这是他于2017年创立的一家私营公司，专注于利用3D组织技术和多组学（基因组学、转录组学、代谢组学）的药物发现和开发。2012年2月至2017年4月，他担任Organovo的总裁兼首席执行官；2012年2月至2017年8月，担任董事长。2007年8月至2012年2月，他曾担任Organovo， Inc. （Organovo的主要运营公司，上市交易前）的总裁、首席执行官和董事长。在创立Organovo之前，从1997年8月到2007年7月，Murphy先生在Amgen， Inc.担任各种职务，包括骨质疏松症/骨癌药物Prolia/Xgeva （denosumab）的全球运营主管。加入Amgen之前，从1993年7月到1997年7月，Murphy先生在Alkermes， Inc.（生物技术公司）任职，在那里他担任他们的第一个批准产品Nutropin （hGH） Depot的开发团队的角色。Murphy先生从2020年8月到2022年2月担任Kintara Therapeutics， Inc.的董事会成员，并在其薪酬委员会、提名和公司治理委员会任职。他持有麻省理工学院化学工程学士学位，是加州大学洛杉矶分校安德森管理学院的校友。
- Keith Murphy re joined the company's Board in July 2020 and has served as the company's Executive Chairman since September 2020. Mr. Murphy is the Chief Executive Officer and Chairman of Viscient Biosciences, Inc. ("Viscient"), a private company that he founded in 2017 that is focused on drug discovery and development utilizing 3D tissue technology and multi omics (genomics, transcriptomics, metabolomics). Mr. Murphy previously served as the company's President and Chief Executive Officer from February 2012 through April 2017, and as Chairman from February 2012 through August 2017. Mr. Murphy also previously served as President, Chief Executive Officer, and Chairman of Organovo, Inc., the company's primary operating company prior to its going public transaction, from August 2007 to February 2012. Prior to founding Organovo, Inc., Mr. Murphy served in various roles at Amgen, Inc. from August 1997 to July 2007 including as Global Operations Leader for the osteoporosis/bone cancer drug Prolia/Xgeva (denosumab). Prior to joining Amgen, Mr. Murphy served at Alkermes, Inc., a biotechnology company, from July 1993 to July 1997, where he played a role on the development team for their first approved product, Nutropin (hGH) Depot. Mr. Murphy has served as a member of the board of directors of Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) since March 2025 and served as a member of the board of directors of Kintara Therapeutics, Inc. from August 2020 to February 2022, and served on its compensation committee and nominating and corporate governance committee. He holds a B.S. in Chemical Engineering from MIT and is an alumnus of the UCLA Anderson School of Management.
高管简历
中英对照 | 中文 | 英文- Jerome D. Jabbour
JeromeD.Jabbour于2018年3月被任命为首席执行官。他自2016年3月起担任我们的总裁。此前，他曾担任我们的执行Vice President、首席商务官、总法律顾问和秘书（2013年10月以来），以及我们的董事之一（2012年4月至2013年11月）。Jabbour先生也是Matinas Biopharma的联合创始人。在加入我们的管理团队之前，他于2012年至2013年10月担任MediMedia USA或MediMedia的执行Vice President and General Counsel，这是一家私人控股的多元化医疗保健服务公司。此前，他曾担任Wockhardt Limited公司（全球制药和生物技术公司）（2008年至2012年）的高级副总裁，的全球法律事务主管，以及Reliant公司的高级法律顾问兼助理秘书（2004年至2008年）。职业生涯早期，他曾担任Alpharma，Inc.的商业顾问（2003年至2004年），以及Lowenstein Sandler LLP的公司助理（1999年至2003年）。Jabbour先生在新泽西的Seton Hall University School of Law获得法学博士学位，在巴尔的摩的Loyola University获得心理学学士学位。
Jerome D. Jabbour was appointed Chief Executive Officer in March 2018 and was named Chairman in March 2025. He has served as Matinas Biopharma Holdings, Inc.'s President since March 2016. Prior to that he served as Matinas Biopharma Holdings, Inc.'s Executive Vice President, Chief Business Officer, General Counsel and Secretary since October 2013 and as one of Matinas Biopharma Holdings, Inc.'s directors from April 2012 until November 2013. Mr. Jabbour is also a Co founder of Matinas BioPharma. Jabbour has also served on the board of directors of Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments since February 2026. Prior to joining Matinas Biopharma Holdings, Inc.'s management team, he was the Executive Vice President and General Counsel of MediMedia USA, or MediMedia, from 2012 to October 2013, a privately held diversified healthcare services company. Prior to MediMedia, he was the Senior Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008 2012), a global pharmaceutical and biotechnology company, and Senior Counsel and Assistant Secretary at Reliant (2004 2008). Earlier in his career, he held positions as Commercial Counsel at Alpharma, Inc. (2003 2004) and as a Corporate Associate at Lowenstein Sandler LLP (1999 2003). Mr. Jabbour earned his J.D. from Seton Hall University School of Law in New Jersey and a B.A. in Psychology from Loyola University in Baltimore.- JeromeD.Jabbour于2018年3月被任命为首席执行官。他自2016年3月起担任我们的总裁。此前，他曾担任我们的执行Vice President、首席商务官、总法律顾问和秘书（2013年10月以来），以及我们的董事之一（2012年4月至2013年11月）。Jabbour先生也是Matinas Biopharma的联合创始人。在加入我们的管理团队之前，他于2012年至2013年10月担任MediMedia USA或MediMedia的执行Vice President and General Counsel，这是一家私人控股的多元化医疗保健服务公司。此前，他曾担任Wockhardt Limited公司（全球制药和生物技术公司）（2008年至2012年）的高级副总裁，的全球法律事务主管，以及Reliant公司的高级法律顾问兼助理秘书（2004年至2008年）。职业生涯早期，他曾担任Alpharma，Inc.的商业顾问（2003年至2004年），以及Lowenstein Sandler LLP的公司助理（1999年至2003年）。Jabbour先生在新泽西的Seton Hall University School of Law获得法学博士学位，在巴尔的摩的Loyola University获得心理学学士学位。
- Jerome D. Jabbour was appointed Chief Executive Officer in March 2018 and was named Chairman in March 2025. He has served as Matinas Biopharma Holdings, Inc.'s President since March 2016. Prior to that he served as Matinas Biopharma Holdings, Inc.'s Executive Vice President, Chief Business Officer, General Counsel and Secretary since October 2013 and as one of Matinas Biopharma Holdings, Inc.'s directors from April 2012 until November 2013. Mr. Jabbour is also a Co founder of Matinas BioPharma. Jabbour has also served on the board of directors of Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments since February 2026. Prior to joining Matinas Biopharma Holdings, Inc.'s management team, he was the Executive Vice President and General Counsel of MediMedia USA, or MediMedia, from 2012 to October 2013, a privately held diversified healthcare services company. Prior to MediMedia, he was the Senior Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008 2012), a global pharmaceutical and biotechnology company, and Senior Counsel and Assistant Secretary at Reliant (2004 2008). Earlier in his career, he held positions as Commercial Counsel at Alpharma, Inc. (2003 2004) and as a Corporate Associate at Lowenstein Sandler LLP (1999 2003). Mr. Jabbour earned his J.D. from Seton Hall University School of Law in New Jersey and a B.A. in Psychology from Loyola University in Baltimore.